Former U.S. President Donald Trump’s recent assertion that “Ireland was very smart, they took our pharmaceutical companies away” is drawing criticism for oversimplifying complex global trade dynamics. While Ireland has indeed become a key hub for pharmaceutical manufacturing, the claim that it “took” the U.S. drug industry is not entirely accurate.
There are currently about 90 pharmaceutical plants in Ireland compared to roughly 1,500 in the U.S., reflecting America’s dominant footprint in the industry. However, major pharmaceutical firms maintain manufacturing operations across multiple countries, and Ireland has emerged as a significant beneficiary of U.S. pharmaceutical investment.
Irish exports of pharmaceutical products to the U.S. reached €44 billion last year, making pharmaceuticals the country’s top export to America. Trump has floated the idea of imposing a 25% tax on drugs produced outside the U.S., which could directly impact Ireland’s lucrative pharma trade. However, the Irish government has been pushing for any pharmaceutical-related tariffs to be included in broader EU-U.S. trade negotiations.
That possibility seems unlikely. U.S. Commerce Secretary Howard Lutnick recently stated that pharmaceutical tariffs are “not available for negotiation” and will remain outside discussions involving reciprocal tariffs with the EU. Echoing Trump’s concerns, Lutnick emphasized the need to bring medicine manufacturing back to American soil, citing vulnerabilities exposed during the COVID-19 pandemic.
In the meantime, the U.S. has temporarily paused a 20% tariff on EU imports during a 90-day negotiation window, opting instead for a 10% baseline tariff on most goods. However, for many Irish exporters—particularly in the food and drink sectors—this represents a significant increase. Ireland exports around €1.9 billion worth of food and beverages annually to the U.S., including key products like whiskey and butter.
While Ireland dodged the steepest tariffs aimed at the EU’s car, steel, and aluminum industries, further risks loom on the tech front. The semiconductor industry, vital to everything from smartphones to vehicles, is another potential flashpoint.
Ireland is home to operations from 15 of the world’s top 30 semiconductor companies, employing over 20,000 people. Intel, the sector’s biggest investor in Ireland, has spent €30 billion on operations including its flagship plant in Leixlip, County Kildare. Although chips have so far avoided U.S. tariffs, the Biden-era CHIPS Act—and Trump’s continued push to localize tech production—suggest future duties could hit Irish-made semiconductors.
U.S. efforts to reshore chip manufacturing face steep challenges. Taiwan Semiconductor (TSMC), building a $165 billion facility in Arizona with $6.6 billion in U.S. funding, has struggled to find skilled workers, underscoring the hurdles in building domestic capacity quickly.
Meanwhile, Trump’s latest decision to exclude all but China from new tariffs briefly stabilized financial markets. But with the dollar down 10% against the euro since January and investor confidence shaky, experts remain skeptical about the long-term impact of aggressive tariff strategies.
Whether Trump can navigate complex trade negotiations without sparking further economic turbulence remains to be seen.
